| Bioactivity | Etomidate-d5 is deuterium labeled Etomidate. Etomidate (R 16659) is a potent GABAA receptor agonist. Etomidate is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia[1][2]. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| Name | Etomidate-d5 |
| Formula | C14H11D5N2O2 |
| Molar Mass | 249.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here? Crit Care, 2012. 16(6): p. 189. [3]. Veronica A Preda, et al. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012 Aug;167(2):137-43. |